A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion (MpeTK01)

NCT01997190 Phase 1 COMPLETED

This is a phase I study of intrapleural AdV-tk therapy in patients with malignant pleural effusion (MPE). The primary objective is to test the safety of intrapleural AdV-tk therapy. Secondary objectives are to evaluate clinical efficacy and biologic activity

Details

Lead sponsor	Candel Therapeutics, Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	19
Start date	2013-10
Completion	2018-02

Conditions

• Malignant Pleural Effusion
• Lung Cancer
• Mesothelioma
• Breast Cancer
• Ovarian Cancer

Interventions

• AdV-tk + valacyclovir

Primary outcomes

• Incidence of treatment emergent adverse events — 8 weeks

Countries

United States